Menu
GWAS Study

A large-scale exome array analysis of venous thromboembolism.

Lindström S, Brody JA, Turman C et al.

30659681 PubMed ID
GWAS Study Type
26277 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

LS
Lindström S
BJ
Brody JA
TC
Turman C
GM
Germain M
BT
Bartz TM
SE
Smith EN
CM
Chen MH
PM
Puurunen M
CD
Chasman D
HJ
Hassler J
PN
Pankratz N
BS
Basu S
GW
Guan W
GB
Gyorgy B
IM
Ibrahim M
EJ
Empana JP
OR
Olaso R
JR
Jackson R
BS
Braekkan SK
MB
McKnight B
DJ
Deleuze JF
OC
O'Donnell CJ
JX
Jouven X
FK
Frazer KA
PB
Psaty BM
WK
Wiggins KL
TK
Taylor K
RA
Reiner AP
HS
Heckbert SR
KC
Kooperberg C
RP
Ridker P
HJ
Hansen JB
TW
Tang W
JA
Johnson AD
MP
Morange PE
TD
Trégouët DA
KP
Kraft P
SN
Smith NL
KC
Kabrhel C
Chapter II

Abstract

Summary of the research findings

Although recent Genome-Wide Association Studies have identified novel associations for common variants, there has been no comprehensive exome-wide search for low-frequency variants that affect the risk of venous thromboembolism (VTE). We conducted a meta-analysis of 11 studies comprising 8,332 cases and 16,087 controls of European ancestry and 382 cases and 1,476 controls of African American ancestry genotyped with the Illumina HumanExome BeadChip. We used the seqMeta package in R to conduct single variant and gene-based rare variant tests. In the single variant analysis, we limited our analysis to the 64,794 variants with at least 40 minor alleles across studies (minor allele frequency [MAF] ~0.08%). We confirmed associations with previously identified VTE loci, including ABO, F5, F11, and FGA. After adjusting for multiple testing, we observed no novel significant findings in single variant or gene-based analysis. Given our sample size, we had greater than 80% power to detect minimum odds ratios greater than 1.5 and 1.8 for a single variant with MAF of 0.01 and 0.005, respectively. Larger studies and sequence data may be needed to identify novel low-frequency and rare variants associated with VTE risk.

8,332 European ancestry cases, 16,087 European ancestry controls, 382 African-American cases, 1,476 African-American controls

Chapter III

Study Statistics

Key metrics and study information

26277
Total Participants
GWAS
Study Type
No
Replicated
European, African American or Afro-Caribbean
Ancestry
France, Norway, U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.